Treatment of Sexual Arousal Disorder in Women
For female sexual arousal disorder, phosphodiesterase type 5 inhibitors (PDE5i) are NOT recommended due to lack of efficacy data and contradictory trial results, despite their theoretical mechanism of increasing pelvic blood flow 1, 2.
Understanding the Clinical Context
Sexual arousal disorder in women presents as either:
- Objective arousal disorder: Lack of lubrication and genital congestion despite sexual stimulation
- Subjective arousal disorder: Decreased perception of arousal despite adequate physiological response
- These frequently coexist and are now grouped with desire disorders in DSM-V due to overlapping etiologies 3
Critical pitfall: There is poor correlation between physiological genital response and subjective arousal perception, making clinical assessment challenging 3.
Treatment Algorithm
First-Line Interventions
1. For Postmenopausal Women with Vaginal Atrophy:
Start with a stepwise approach 4:
- Step 1: Lubricants for all sexual activity PLUS vaginal moisturizers
- Step 2: If inadequate response or severe symptoms → low-dose vaginal estrogen (pills, rings, or creams) 4, 1
- This has strong evidence for treating vaginal dryness, itching, and painful intercourse in postmenopausal women
2. Cognitive Behavioral Therapy (CBT):
- CBT, particularly mindfulness-based approaches, significantly improves arousal, desire, and orgasm 1, 5
- Most recent meta-analysis (2026) demonstrates clear efficacy across all domains 5
- Should be offered alongside or before pharmacological options
3. Integrative Therapies:
- Yoga and meditation may be helpful 1
- Pelvic floor physiotherapy improves arousal, lubrication, orgasm, and satisfaction 1
Prescription Options (When Conservative Measures Fail)
For Postmenopausal Women:
Vaginal DHEA (prasterone) - FDA approved 2016:
- Improves sexual desire, arousal, pain, and overall function 1
- RCT of 441 cancer survivors showed significant improvements without clinically important systemic estrogenic activity
- Caution: FDA label warns against use in women with breast cancer history; limited safety data in hormonally-mediated cancers 1
Ospemifene (SERM):
- FDA approved 2013 for moderate-to-severe dyspareunia
- Effective for vaginal dryness and dyspareunia 1
- Contraindicated: Women with current or history of breast cancer 1
For Premenopausal Women with Desire/Arousal Overlap:
Flibanserin - FDA approved 2015:
- Improves total sexual function and desire 1
- Most recent meta-analysis (2026) confirms efficacy for desire specifically 5
- Results in approximately 1 additional satisfying sexual event every 2 months
- Not studied in cancer populations but reasonable option
Bremelanotide:
- Recent meta-analysis (2026) shows improvement in both desire AND arousal 5
- Improves total sexual function and reduces distress
Alternative options (limited evidence):
- Bupropion or buspirone for hypoactive desire with arousal overlap 1
Adjunctive Treatments
- Topical lidocaine: For persistent introital pain affecting arousal 4, 1
- Vaginal dilators: For vaginismus or stenosis interfering with arousal 4, 1, 2
- Pelvic floor physiotherapy: Should be offered for pain or pelvic floor dysfunction 4, 1
What Does NOT Work
Phosphodiesterase type 5 inhibitors (sildenafil, etc.): Multiple guidelines explicitly state these are NOT recommended for female sexual arousal disorder due to contradictory RCT results despite theoretical benefits 1, 2. This is a critical distinction from male sexual dysfunction.
Key Clinical Considerations
- Assess menopausal status first: Treatment differs significantly between pre- and postmenopausal women
- Screen for contributing factors: Medications (SSRIs, beta-blockers, narcotics), cardiovascular disease, diabetes, relationship issues, anxiety/depression 1, 2
- Partner involvement: Encourage partner participation in treatment decisions 4
- Monitor response: If no benefit by 6 months, discontinue treatment 6
- Testosterone therapy: Only evidence-based indication is hypoactive sexual desire disorder, NOT arousal disorder specifically 6
Evidence Strength Note
The evidence base for female sexual arousal disorder treatments remains weaker than for male dysfunction 1, 2. The 2026 meta-analysis provides the strongest recent evidence supporting CBT, flibanserin, and bremelanotide 5. Guidelines consistently recommend a biopsychosocial approach combining psychological interventions with targeted pharmacotherapy based on specific symptoms rather than arousal disorder alone.